Gilead Sciences (NASDAQ:GILD) unit Kite has filed a supplemental marketing application to the FDA seeking approval of Yescarta (axicabtagene ciloleucel) for the treatment of relapsed/refractory follicular lymphoma and marginal zone lymphoma after two or more prior lines of systemic therapy, both Breakthrough Therapy-tagged indications.
The CAR T therapy was approved in the U.S. almost three years ago for certain types of non-Hodgkin lymphoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.